Accenture plc (ACN) PT Raised to $430 at RBC Capital

Accenture plc (ACN) PT Raised to $460 at BMO Capital

BMO Capital analyst Keith Bachman raised the price target on Accenture plc (NYSE: ACN) to $460.00 (from $385.00) while maintaining a Market Perform rating.

The analyst commented, "Accenture delivered what can only be described as an excellent Q. We have been bullish on IT... More

Accenture plc (ACN) PT Raised to $433 at Piper Sandler Following EPS

Piper Sandler analyst Arvind Ramnani raised the price target on Accenture plc (NYSE: ACN) to $433.00 (from $354.00) while maintaining a Neutral rating following earnings.

Accenture plc (ACN) PT Raised to $440 at Stifel Following Earnings

Stifel analyst David Grossman raised the price target on Accenture plc (NYSE: ACN) to $440.00 (from $385.00) while maintaining a Buy rating following strong results.

The analyst commented, "F1Q results exceeded all metrics with revenue growth accelerating (two year stack) reflecting acceleration of digital... More

Accenture plc (ACN) PT Raised to $450 at Wedbush Following EPS

Wedbush analyst Moshe Katri raised the price target on Accenture plc (NYSE: ACN) to $450.00 (from $350.00) while maintaining a Outperform rating following strong results.

"We believe the pandemic-driven, multi-year spending cycle on digital transformation initiatives will likely continue to
drive strong industry growth," the analyst said.

Pre-Open Stock Movers 12/16: (VRCA) (VALN) (ACN) Higher; (IRNT) (SNDX) (ADBE) Lower (more...)

Pre-Open Stock Movers:

IronNet (NYSE: IRNT) 25.7% LOWER; reported Q3 EPS of ($2.22), $2.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $6.9 million versus the consensus estimate of $11.79 million.

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) 13.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) acknowledged that Verricas resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) was complete and assigned a Prescription Drug User Fee Act (PDUFA) goal date of... More

Accenture (ACN) Acquires Zestgroup

Accenture (NYSE: ACN) has acquired Zestgroup, a services firm specializing in energy transitions, net carbon-zero projects and procurement of renewables. Terms of the transaction were not disclosed.

Zestgroup brings deep industry knowledge, project expertise and market regulation experience into helping organizations move to net-zero. These capabilities enhance Accentures ability to build more trusted, circular and net-zero value chains while driving social and economic benefits for all stakeholders.

By combining years of deep industry expertise and capabilities, Zestgroup advances our ability to help clients move faster in achieving their carbon emission objectives,... More

Accenture revenue forecast tops estimates on cloud, security services demand

By Chavi Mehta

(Reuters) -IT consulting firm Accenture Plc forecast better-than-expected second-quarter revenue on Thursday, as more clients seek its cloud and security services, sending its shares up more than 10% in premarket trade.

Client spending, which rebounded last fiscal year to pre-pandemic levels due to a shift to hybrid working models, has stayed strong with Accenture reporting robust bookings of $16.8 billion in the... More

Accenture (ACN) Q1 Revenue Tops Consensus, Offers Guidance

Accenture (NYSE: ACN) reported Q1 EPS of $2.78, may not compare to the analyst estimate of $2.35. Revenue for the quarter came in at $15 billion versus the consensus estimate of $12.56 billion.

GUIDANCE:

Accenture sees Q2 2022 revenue of $14.3-14.75 billion, versus the consensus of $12.5 billion.

Accenture sees FY2022 EPS of $10.32-$10.60, may not compare versus the consensus of $9.01.